Publications: Sandra Barbosu

The United States shoulders the cost of global drug innovation—unless wealthy nations pay their fair share, future cures will stall.

To stay ahead in biopharma and ensure new therapies work for everyone, the U.S. must fix the diversity gap in biomedical research.

Follow-on biopharmaceutical innovations deliver substantial health and economic benefits by improving the safety and efficacy of existing therapies, addressing unmet patient needs, expanding therapeutic applications, and enhancing adherence. Supportive policies are essential to sustain progress and ensure broad access to these medical advances.

Recent policies permitting CMS price setting are hamstringing the U.S. biopharmaceutical industry, as they reduce incentives for pharmaceutical companies to invest in future drug R&D to create life-improving and life-saving medicines.

The Inflation Reduction Act (IRA) undermines innovation in small-molecule drugs by subjecting them to price controls after 9 years, whereas large-molecule drugs (biologics) are allowed 13 years of market pricing. Congress should pass the bipartisan EPIC Act to remedy this issue.

Cutting federal life sciences funding threatens U.S. biopharmaceutical innovation, while China is ramping up investment to dominate the industry.

The FDA’s Breakthrough Therapy Designation program underscores the benefits of targeted regulatory innovation. Its success offers valuable lessons for policymakers navigating the balance between speed and safety in approving life-saving therapies.

America’s poor health outcomes aren’t about bad care—they’re about bad habits, and solving them starts long before the doctor’s office.

Many of the world’s biggest challenges are health challenges. The good news is that, more than ever, people are meeting these challenges with innovative solutions.

AI has the potential to transform drug development by enhancing productivity across the entire development pipeline, boosting biopharmaceutical innovation, accelerating the delivery of new therapies, and fostering competition to help improve public health outcomes.